SCHEMBL8996727

SCHEMBL8996727

OC[C@H]1OC(OC(OC2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c2ccccc2)[C@H](O)[C@@H](O)[C@@H]1O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYNJ2 O15056 2/20 0.55
KDM4E B2RXH2 1/20 0.55
ABL1 P00519 1/20 0.55
ALPL P05186 1/20 0.55
POLB P06746 1/20 0.55
ALPI P09923 1/20 0.55
GAA P10253 1/20 0.55
MAPT P10636 1/20 0.55
ALPG P10696 1/20 0.55
PABPC1 P11940 1/20 0.55
RECQL P46063 1/20 0.55
GALK1 P51570 1/20 0.55
CASP7 P55210 1/20 0.55
CASP6 P55212 1/20 0.55
MCL1 Q07820 1/20 0.55
RIN1 Q13671 1/20 0.55
EIF4H Q15056 1/20 0.55
CD209 Q9NNX6 2/20 0.53
TYR P14679 1/20 0.49
ATM Q13315 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7155388 1.00 SYNJ2 (0.55) SYNJ2KDM4EABL1ALPLPOLB
SCHEMBL8604757 1.00 SYNJ2 (0.55) SYNJ2KDM4EABL1ALPLPOLB
SCHEMBL8656458 1.00 SYNJ2 (0.55) SYNJ2KDM4EABL1ALPLPOLB
SCHEMBL8718358 1.00 SYNJ2 (0.55) SYNJ2KDM4EABL1ALPLPOLB
SCHEMBL14655998 0.98 SYNJ2 (0.53) SYNJ2KDM4EABL1ALPLPOLB
SCHEMBL24837353 0.88 SYNJ2 (0.55) SYNJ2KDM4EABL1ALPLPOLB
SCHEMBL4984171 0.88 SYNJ2 (0.55) SYNJ2KDM4EABL1ALPLPOLB
SCHEMBL27757445 0.87 SYNJ2 (0.54) SYNJ2KDM4EABL1ALPLPOLB
SCHEMBL3636324 0.85 SYNJ2 (0.59) SYNJ2KDM4EABL1ALPLPOLB
SCHEMBL17296029 0.85 SYNJ2 (0.56) SYNJ2KDM4EABL1ALPLPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180118884-A1 USE OF CO2 FOR THE SYNTHESIS OF CYCLIC GLYCOCARBONATES AND LINEAR POLYGLYCOCARBONATES BY POLYCONDENSATION FROM GLYCANS UNIV KING ABDULLAH SCI & TECH (SA) 2018-05-03 US disclosed
EP-3283498-A1 USE OF CO2 FOR THE SYNTHESIS OF CYCLIC GLYCOCARBONATES AND LINEAR POLYGLYCOCARBONATES BY POLYCONDENSATION FROM GLYCANS King Abdullah University Of Science And Technology (SA) 2018-02-21 EP disclosed
WO-2016166682-A1 USE OF CO2 FOR THE SYNTHESIS OF CYCLIC GLYCOCARBONATES AND LINEAR POLYGLYCOCARBONATES BY POLYCONDENSATION FROM GLYCANS KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) 2016-10-20 WO disclosed
US-5514662-A HIV INFECTIONS LABORATOIRES MAYOLY SPINDLER (S.A.R.L.) (FR) 1996-05-07 US disclosed
WO-1993009791-A2 USE OF AMPHOTERICIN B DERIVATIVES AS PROTEASE INHIBITORS LABORATOIRES MAYOLY SPINDLER (S.A.R.L.) (FR) 1993-05-27 WO disclosed
EP-0542630-A2 Use of derivatives of amphotericin B as protease inhibitors LABORATOIRES MAYOLY SPINDLER S.A.R.L. (FR) 1993-05-19 EP disclosed
US-5095020-A Antitumor agents DUPHAR INTERNATIONAL RESEARCH B.V. (NL) 1992-03-10 US disclosed
EP-0357122-A2 Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties DUPHAR INTERNATIONAL RESEARCH B.V (NL) 1990-03-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180118884-A1 USE OF CO2 FOR THE SYNTHESIS OF CYCLIC GLYCOCARBONATES AND LINEAR POLYGLYCOCARBONATES BY POLYCONDENSATION FROM GLYCANS ALG1, CSGALNACT1, ALG8 SYNJ2 1089/4885KDM4E 3568/4885ABL1 4729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.